Background/Aim Sorafenib has been the historical first-line treatment of choice for unresectable or metastatic hepatocellular carcinoma (HCC) since 2007. However, on May 29, 2020, FDA approved atezolizumab plus bevacizumab (AB) combination for HCC and gave it priority over sorafenib. Here, we performed a systematic review evaluating the efficacy and safety of combination immunogenic chemotherapy as first-line therapy as opposed to sorafenib (S) and atezolizumab (A) monotherapies.
Abstract BACKGROUND Despite the use of the current standard therapy, the prognosis of unresectable hepatocellular carcinoma (HCC) patients is poor, with median survival times of 40 mo in intermediate HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] and 6–8 mo in advanced HCC (BCLC stage C). Although patients with early-stage HCC are usually suitable for therapies with curative intention, up to 70% of patients may manifest disease relapses at 5-year surveillance. Within the past decade, t...
Prevalence of complex sleep apnea syndrome (ComSAS) is growing after its true characterization and clinical presentation, which enhances an appropriate diagnostic approach for its better treatment and outcome. Complex sleep apnea is a form of sleep-disordered breathing in which patients have respiratory control dysfunction and upper airway obstruction; it often clinically presents as central sleep apnea (CSA) and is mostly seen in obstructive sleep apnea (OSA) patients during the initial phas...
